Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
ACE-031 1 mg
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
ACE-031 (Ramatercept) is a soluble fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to a human IgG1-Fc region. By acting as a decoy receptor ('ligand trap'), it sequesters multiple TGF-β superfamily ligands — myostatin, activin A/B, GDF-11, BMP-9, BMP-10 — preventing their binding to native ACVR2B. Research applications include broad TGF-β superfamily pathway investigation, myostatin/activin pathway dissection, and ligand trap pharmacology.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C133H227N43O33 |
|---|---|
| Synonyms | UNII-U8DGS69FVC, Myostatin inhibitory peptide 7, U8DGS69FVC, CHEMBL3410227, Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2, BDBM50071379, ACE-031 Myostatin inhibitory peptide 7 |
| Molar Mass | 2956.5 g/mol |
| CAS Number | 1621169-52-5 |
| PubChem CID | 118732224 |
| Total Compound Content | 1 mg per vial |
| Shelf Life | 24 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
Why does ACE-031 differ from myostatin-selective inhibitors in research applications?
ACE-031 functions as a soluble ActRIIB ligand trap, binding multiple ActRIIB ligands including myostatin, activins, GDF-11, BMP-9, and BMP-10. This broad ligand-binding profile allows investigation of combined ActRIIB pathway suppression rather than isolated myostatin inhibition. In contrast, myostatin-selective approaches target GDF-8 specifically, making ACE-031 a valuable tool for studying the integrated contribution of multiple ActRIIB ligands to signalling, tissue regulation, and pathway cross-talk.
How does ACE-031 differ from myostatin-specific antibodies?
ACE-031 acts upstream as a receptor-based ligand trap that sequesters multiple ActRIIB-binding growth factors, whereas myostatin-specific antibodies selectively neutralize GDF-8 alone. This distinction allows researchers to compare broad ActRIIB pathway inhibition with highly selective myostatin blockade and evaluate the biological consequences of each approach across different experimental systems.
What endpoints are commonly evaluated in ACE-031 research?
Common endpoints include skeletal muscle mass, muscle fibre morphology, muscle function measurements, ActRIIB pathway biomarkers, Smad2/3 signalling activity, bone-related signalling markers, and expression of genes regulated by myostatin and activin pathways. These endpoints help characterize the effects of broad ActRIIB ligand sequestration and distinguish pathway-specific from multi-ligand responses.
-
-
-
SALE
-
-
-
